Heparin-Natrium Multi Braun

Heparin‑Natrium Multi Braun is a prescription anticoagulant that contains the active ingredient heparin sodium. The product’s strength is not specified, and the dosage form is not detailed, but it is supplied for intravenous or subcutaneous administration. It belongs to the antithrombotic drug class, is marketed in the European Union, and is used under medical supervision to manage clot‑related conditions in hospital settings for acute care.

Heparin‑Natrium Multi Braun is indicated for clinical situations where inhibition of clot formation is required.

- Prevention and treatment of venous thromboembolism, including deep‑vein thrombosis and pulmonary embolism. - Prophylaxis of clot formation in patients undergoing major surgery or orthopedic procedures. - Anticoagulation during extracorporeal circulation such as hemodialysis, cardiopulmonary bypass, or plasma exchange. - Management of acute coronary syndromes when combined with other antithrombotic agents. - Prevention of catheter‑related thrombosis in central venous access devices.

Adverse reactions to Heparin‑Natrium Multi Braun reflect its anticoagulant activity and may involve bleeding or immune‑mediated events.

Common: - Minor bleeding at injection sites or from mucous membranes. - Bruising or hematoma formation. - Localized pain or erythema at the injection area. - Transient elevation of liver enzymes. - Nausea or mild headache.

Serious: - Major hemorrhage, including gastrointestinal or intracranial bleeding. - Heparin‑induced thrombocytopenia (HIT) with a risk of new thrombosis. - Spontaneous adrenal or retroperitoneal hemorrhage. - Severe allergic reactions such as anaphylaxis. - Disseminated intravascular coagulation (rare).

Use of Heparin‑Natrium Multi Braun requires careful assessment of bleeding risk and monitoring of coagulation parameters.

- Assess patient history for active bleeding, recent surgery, or trauma before initiating therapy. - Monitor activated partial thromboplastin time (aPTT) or anti‑Xa levels to maintain therapeutic range. - Use caution in patients with renal or hepatic impairment, adjusting dose as needed. - Avoid use in individuals with known hypersensitivity to heparin or pork‑derived products. - Consider alternative anticoagulation during pregnancy, as safety data are limited. - Discontinue or reduce dose prior to invasive procedures to minimize bleeding. - Educate patients about signs of bleeding and thrombocytopenia.

Heparin‑Natrium Multi Braun can interact with other agents that affect hemostasis or drug metabolism.

Avoid: - Concurrent use of other anticoagulants (e.g., warfarin, direct oral anticoagulants) without specialist guidance. - Antiplatelet drugs such as aspirin, clopidogrel, or ticagrelor. - Thrombolytic agents (e.g., alteplase, streptokinase). - Non‑steroidal anti‑inflammatory drugs (NSAIDs) that increase bleeding risk.

Use with caution: - ACE inhibitors and angiotensin receptor blockers, which may potentiate hypotension during rapid infusion. - Corticosteroids, which can increase gastrointestinal bleeding risk. - Certain antibiotics (e.g., vancomycin, aminoglycosides) that may affect platelet function. - Lipid‑lowering agents such as statins, which have rare reports of enhanced anticoagulant effect.